Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1250 of 1463 entries
View as:

Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03387774 Org: User:
Start: 01/30/18 End: 01/31/24 Due: 01/31/25

Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT03939975 Org: User:
Start: 06/01/19 End: 07/31/19 Due: 07/31/20

WHO Mental Health Gap Action Program (mhGAP) for Improving Child Mental and Behavioral Disorder Service Quality in China

Phase: N/A Priority: Normal
NCT ID: NCT06702410 Org: User:
Start: 11/20/24 End: 02/20/26 Due: 02/20/27

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04715633 Org: User:
Start: 12/01/20 End: 07/31/25 Due: 07/31/26

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Phase: N/A Priority: Normal
NCT ID: NCT05941741 Org: User:
Start: 01/10/24 End: 12/31/29 Due: 12/31/30

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Phase: N/A Priority: Normal
NCT ID: NCT04627363 Org: User:
Start: 01/01/21 End: 06/30/23 Due: 06/30/24

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT03854838 Org: User:
Start: 05/01/19 End: 02/01/23 Due: 02/01/24

Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)

Phase: N/A Priority: Normal
NCT ID: NCT06524427 Org: User:
Start: 08/26/20 End: 12/31/30 Due: 12/31/31

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Phase: N/A Priority: Normal
NCT ID: NCT05357846 Org: User:
Start: 11/01/22 End: 01/31/31 Due: 01/31/32

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Phase: N/A Priority: Normal
NCT ID: NCT04548440 Org: User:
Start: 08/31/20 End: 12/31/22 Due: 12/31/23

SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05319574 Org: User:
Start: 04/24/22 End: 05/31/26 Due: 05/31/27

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Phase: N/A Priority: Normal
NCT ID: NCT05214339 Org: User:
Start: 03/16/22 End: 06/01/23 Due: 06/01/24

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Phase: N/A Priority: Normal
NCT ID: NCT06262581 Org: User:
Start: 09/23/23 End: 12/31/25 Due: 12/31/26

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT04769908 Org: User:
Start: 02/23/21 End: 12/01/21 Due: 12/01/22

Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT04143191 Org: User:
Start: 09/15/19 End: 09/15/23 Due: 09/15/24

Artificial Intelligence Screening on Patients With Primary Angle Closure Glaucoma

Phase: N/A Priority: Normal
NCT ID: NCT03611387 Org: User:
Start: 04/01/18 End: 12/31/19 Due: 12/31/20

Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04341883 Org: User:
Start: 11/13/19 End: 12/31/23 Due: 12/31/24

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04778956 Org: User:
Start: 03/03/21 End: 03/03/33 Due: 03/03/34

Instant and Lasting Relief Effects of Strontium Chloride/Potassium Nitrate Dentifrice on Dentin Hypersensitivity

Phase: N/A Priority: Normal
NCT ID: NCT01426360 Org: User:
Start: 09/30/11 End: 09/30/11 Due: 09/30/12

The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure

Phase: N/A Priority: Normal
NCT ID: NCT02489864 Org: User:
Start: 07/31/15 End: 12/31/17 Due: 12/31/18

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06061263 Org: User:
Start: 05/01/22 End: 12/31/23 Due: 12/31/24

Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03702868 Org: User:
Start: 10/10/18 End: 10/30/20 Due: 10/30/21

Nomogram for Predicting Biliary Complication

Phase: N/A Priority: Normal
NCT ID: NCT06658665 Org: User:
Start: 11/01/24 End: 12/30/24 Due: 12/30/25

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06740370 Org: User:
Start: 12/13/24 End: 08/30/26 Due: 08/30/27

Hematoporphyrin Photodynamic Therapy for Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06437288 Org: User:
Start: 09/18/24 End: 12/01/30 Due: 12/01/31